Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development. Its drug candidates are discovered and developed internally, using its chemical compound library and integrated discovery engine. During the year ended December 31, 2011, it initiated a Phase 2b/3 clinical trial (GALAXY) of ganetespib in combination with docetaxel in non-small cell lung cancer (NSCLC). As of December 31, 2011, it had two clinical-stage programs and one preclinical-stage program in oncology. In 2011, in addition to focusing on ganetespib program, the Company also focused on its elesclomol and calcium release activated calcium modulator (CRAC) programs.